Market Research Report

A quick peek into the report

1.1   Product Definition
1.1.1   Inclusion and Exclusion
1.2   Market Overview
1.3   Historical Perspective
1.4   Significant Technologies
1.5   Classification of Molecular Diagnostics
1.6   Future Potential

2.1   Patent Analysis
2.1.1   Patent Filing Trend
2.2   Legal Requirements
2.2.1   Legal Requirements and Framework in the U.S.
2.2.2   U.S. FDA Regulations

3.1   Competitive Landscape
3.1.1   Acquisitions
3.1.2   Synergistic Activities
3.1.3   Product Launches and Upgradations
3.1.4   Business Expansion

4.1   Market Dynamics
4.1.1   Impact Analysis
4.1.2   Market Drivers
4.1.2.1   Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East
4.1.2.2   Increase in Awareness and Acceptance of Personalized Medicines in the Middle East
4.1.2.3   Significant External Funding for Executing Research and Development Exercises
4.1.3   Market Restraints
4.1.3.1   Uncertain Reimbursement Scenario
4.1.3.2   Lack of High-Complexity Testing Centers in the Middle East
4.1.4   Market Opportunities
4.1.4.1   Massive Scope for Adoption of Molecular Diagnostics
4.1.4.2   Rise of Next-Generation Ultrasensitive Molecular Diagnostics
4.1.4.3   Novel Revenue Streams
4.2   COVID-19 Impact on Middle East Molecular Diagnostics Market
4.2.1   Impact on Market Size
4.2.2   Impact on Molecular Diagnostic Practices

5.1   Overview
5.1.1   Systems
5.1.2   Kits and Consumables
5.1.3   Software and Other Products

6.1   Overview
6.1.1   Laboratory Testing
6.1.2   Point-of-Care Testing

7.1   Overview
7.1.1   Polymerase Chain Reaction (PCR)
7.1.2   Next-Generation Sequencing
7.1.3   Isothermal Nucleic Acid Amplification Technology (INAAT)
7.1.4   Microarray
7.1.5   In-Situ Hybridization (ISH)
7.1.6   Immunohistochemistry (IHC)
7.1.7   Other Technologies

8.1   Overview
8.1.1   Core Molecular Diagnostics
8.1.2   Reproductive Genetics
8.1.3   Companion Diagnostics (CDx)
8.1.4   Liquid Biopsy
8.1.5   Other Applications

9.1   Overview
9.1.1   Hospitals
9.1.2   Diagnostic Centers
9.1.3   Out-Patient Clinics/General Practitioners
9.1.4   Research Laboratories
9.1.5   Other End Users

10.1   Overview
10.1.1   Kingdom of Saudi Arabia (KSA)
10.1.2   Israel
10.1.3   United Arab Emirates (U.A.E.)
10.1.4   Egypt
10.1.5   Iran
10.1.6   Qatar
10.1.7   Rest-of-the-Middle East

11.1   Overview
11.2   Abbott.
11.2.1   Company Overview
11.2.2   Role of Abbott. in the Middle East Molecular Diagnostics Market
11.2.3   Key Competitors of the Company
11.2.4   Key Customers of the Company
11.2.5   Business Strategies
11.2.6   Financials
11.2.7   Key Insights about Financial Health of the Company
11.2.8   SWOT Analysis
11.3   Agilent Technologies, Inc.
11.3.1   Company Overview
11.3.2   Role of Agilent Technologies, Inc. in the Middle East Molecular Diagnostics Market
11.3.3   Key Competitors of the Company
11.3.4   Key Customers of the Company
11.3.5   Business Strategies
11.3.6   Corporate Strategies:
11.3.7   Financials
11.3.8   Key Insights about Financial of the Company
11.3.9   SWOT Analysis
11.4   bioMérieux SA
11.4.1   Company Overview
11.4.2   Role of bioMérieux SA in the Middle East Molecular Diagnostics Market
11.4.3   Key Competitors of the Company
11.4.4   Key Customers of the Company
11.4.5   Business Strategies
11.4.6   Financials
11.4.7   Key Insights about the Financial Health of the Company
11.4.8   SWOT Analysis
11.5   BD.
11.5.1   Company Overview
11.5.2   Role of BD. in the Middle East Molecular Diagnostics Market
11.5.3   Key Competitors of the Company
11.5.4   Key Customers of the Company
11.5.5   Business Strategies
11.5.6   Financials
11.5.7   Key Insights about Financial Health of the Company
11.5.8   SWOT Analysis
11.6   Babirus Medical Equipment LLC
11.6.1   Company Overview
11.6.2   Role of Babirus Medical Equipment Trading LLC in the Middle East Molecular Diagnostics Market
11.6.3   Key Competitors of the Company
11.6.4   Key Customers of the Company
11.6.5   Business Strategies
11.6.6   SWOT Analysis
11.7   Bio-Rad Laboratories, Inc.
11.7.1   Company Overview
11.7.2   Role of Bio-Rad Laboratories, Inc. in the Middle East Molecular Diagnostics Market
11.7.3   Key Competitors of the Company
11.7.4   Key Customers of the Company
11.7.5   Business Strategies
11.7.5.1   Corporate Strategies
11.7.6   Financials
11.7.7   Key Insights about Financial Health of the Company
11.7.8   SWOT Analysis
11.8   Danaher.
11.8.1   Company Overview
11.8.2   Role of Danaher. in the Middle East Molecular Diagnostics Market
11.8.3   Key Competitors of the Company
11.8.4   Key Customers of the Company
11.8.5   Business Strategies
11.8.6   Corporate Strategies
11.8.7   Financials
11.8.8   Key Insights about Financial Health of the Company
11.8.9   SWOT Analysis
11.9   F. Hoffmann-La Roche Ltd.
11.9.1   Company Overview
11.9.2   Role of F. Hoffmann-La Roche Ltd. in the Middle East Molecular Diagnostics Market
11.9.3   Key Competitors of the Company
11.9.4   Key Customers of the Company
11.9.5   Business Strategies
11.9.6   Corporate Strategies
11.9.7   Financials
11.9.8   Key Insights about Financial Health of the Company
11.9.9   SWOT Analysis
11.10 Guardant Health
11.10.1   Company Overview
11.10.2   Role of Guardant Health in the Middle East Molecular Diagnostics Market
11.10.3   Key Competitors of the Company
11.10.4   Key Customers of the Company
11.10.5   Corporate Strategies
11.10.6   Financials
11.10.7   Key Insights about Financial Health of the Company
1.1.1   SWOT Analysis
11.11   Illumina, Inc.
11.11.1   Company Overview
11.11.2   Role of Illumina, Inc. in the Middle East Molecular Diagnostics Market
11.11.3   Key Competitors of the Company
11.11.4   Key Customers of the Company
11.11.5   Corporate Strategies
11.11.6   Financials
11.11.7   Key Insights about the Financial Health of the Company
11.11.8   SWOT Analysis
11.12   QIAGEN N.V.
11.12.1   Company Overview
11.12.2   Role of QIAGEN N.V. in the Middle East Molecular Diagnostics Market
11.12.3   Key Competitors of the Company
11.12.4   Key Customers of the Company
11.12.5   Corporate Strategies
11.12.6   Key Insights about Financial Health of the Company
11.12.7   SWOT Analysis
11.13   Thermo Fisher Scientific Inc.
11.13.1   Company Overview
11.13.2   Role of Thermo Fisher Scientific Inc. in the Middle East Molecular Diagnostics Market
11.13.3   Key Competitors of the Company
11.13.4   Key Customers of the Company
11.13.5   Business Strategies
11.13.6   Financials
11.13.7   Key Insights about Financial Health of the Company
11.13.8   SWOT Analysis

Table 1: COVID-19 Impact on Middle East Molecular Diagnostics Market

Figure 1:   Middle East Molecular Diagnostics Market-Market Dynamics
Figure 2:   Share of Key Market Strategies and Developments, January 2017-September 2021
Figure 3:   Middle East Molecular Diagnostics Market Snapshot, $Million, 2020-2031
Figure 4:   Middle East Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
Figure 5:   Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
Figure 6:   Middle East Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
Figure 7:   Middle East Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
Figure 8:   Middle East Molecular Diagnostics Market Research Methodology
Figure 9:   Middle East Molecular Diagnostics Market: Segmentation
Figure 10:   Role of Diagnostics in Healthcare
Figure 11:   Evolution of Molecular Diagnostics
Figure 12:   Classification of Molecular Diagnostics
Figure 13:   Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019-October 2021
Figure 14:   Share of Key Developments and Strategies, January 2017-September 2021
Figure 15:   Share of Acquisitions (by Company), January 2017-September 2021
Figure 16:   Share of Synergistic Activities (by Company), January 2017-September 2021
Figure 17:   Share of Product Launches and Upgradations (by Company), January 2017-September 2021
Figure 18:   Share of Business Expansion (by Company), July 2017-August 2021
Figure 19:   Middle East Molecular Diagnostics Market - Market Dynamics
Figure 20:   Rate of Cancer Incidence and Death in 2020
Figure 21:   Personalized Care for Cancer Patients
Figure 22:   Impact of COVID-19 on Middle East Molecular Diagnostics Market
Figure 23:   Share of Middle East Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
Figure 24:   Middle East Molecular Diagnostics Market (Systems), $Million, 2020-2031
Figure 25:   General Workflow of a Molecular Diagnostic Kit
Figure 26:   Middle East Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
Figure 27:   Aspects of Software Development
Figure 28:   Middle East Molecular Diagnostics Market (Software and Other Products), $Million, 2020-2031
Figure 29:   Middle East Molecular Diagnostics Market (by Testing Location)
Figure 30:   Share of Middle East Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031
Figure 31:   Middle East Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
Figure 32:   Middle East Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
Figure 33:   Share of Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 34:   Middle East Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
Figure 35:   Middle East Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
Figure 36:   Middle East Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
Figure 37:   Middle East Molecular Diagnostics Market (Microarray), $Million, 2020-2031
Figure 38:   Middle East Molecular Diagnostics Market (ISH), $Million, 2020-2031
Figure 39:   Middle East Molecular Diagnostics Market (IHC), $Million, 2020-2031
Figure 40:   Middle East Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 41:   Middle East Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 42:   Middle East Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
Figure 43:   Middle East Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
Figure 44:   Middle East Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
Figure 45:   Middle East Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
Figure 46:   Middle East Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
Figure 47:   Share of Middle East Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 48:   Middle East Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
Figure 49:   Middle East Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
Figure 50:   Middle East Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
Figure 51:   Middle East Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
Figure 52:   Middle East Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 53:   Middle East Molecular Diagnostics Market (by Country), $Million, 2020-2031
Figure 54:   Middle East Molecular Diagnostics Market (by Country), 2021 and 2031
Figure 55:   Kingdom of Saudi Arabia Diagnostics Market $Million, 2020-2031
Figure 56:   Israel Molecular Diagnostics Market, $Million, 2020-2031
Figure 57:   U.A.E. Molecular Diagnostics Market, $Million, 2020-2031
Figure 58:   Egypt Molecular Diagnostics Market, $Million, 2020-2031
Figure 59:   Iran Molecular Diagnostics Market, $Million, 2020-2031
Figure 60:   Qatar Molecular Diagnostics Market, $Million, 2020-2031
Figure 61:   Rest-of-the-Middle East Molecular Diagnostics Market, $Million, 2020-2031
Figure 62:   Total Number of Companies Profiled
Figure 63:   Abbott.: Overall Product Portfolio
Figure 64:   Abbott.: Overall Financials, 2019-2021
Figure 65:   Abbott.: Revenue (by Segment), 2019-2021
Figure 66:   Abbott.: Revenue (by Region), 2019-2021
Figure 67:   Abbott.: R&D Expenditure, 2019-2021
Figure 68:   Abbott.: SWOT Analysis
Figure 69:   Agilent Technologies, Inc.: Overall Product Portfolio
Figure 70:   Agilent Technologies, Inc.: Overall Financials, 2019-2021
Figure 71:   Agilent Technologies, Inc.: Revenue (by Segment), 2019-2021
Figure 72:   Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
Figure 73:   Agilent Technologies, Inc.: R&D Expenditure, 2019-2021
Figure 74:   Agilent Technologies, Inc.: SWOT Analysis
Figure 75:   bioMérieux SA: Product Portfolio
Figure 76:   bioMérieux SA: Overall Financials, $Million, 2019-2021
Figure 77:   bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 78:   bioMérieux SA: Revenue (by Region), $Million, 2019-2021
Figure 79:   bioMérieux SA: R&D Expenditure, $Million, 2019-2021
Figure 80:   bioMérieux SA: SWOT Analysis
Figure 81:   BD.: Overall Product Portfolio
Figure 82:   BD.: Overall Financials, 2019-2021
Figure 83:   BD.: Revenue (by Segment), 2019-2021
Figure 84:   BD.: Revenue (by Region), 2019-2021
Figure 85:   BD.: R&D Expenditure, 2019-2021
Figure 86:   BD.: SWOT Analysis
Figure 87:   Babirus Medical Equipment Trading LLC: Overall Product Portfolio
Figure 88:   Babirus Medical Equipment Trading LLC: SWOT Analysis
Figure 89:   Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 90:   Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
Figure 91:   Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021
Figure 92:   Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
Figure 93:   Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
Figure 94:   Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 95:   Danaher.: Overall Product Portfolio
Figure 96:   Danaher.: Overall Financials, 2019-2021
Figure 97:   Danaher.: Revenue (by Segment), 2019-2021
Figure 98:   Danaher.: Revenue (by Region), 2019-2021
Figure 99:   Danaher.: R&D Expenditure, 2019-2021
Figure 100:   Danaher.: SWOT Analysis
Figure 101:   F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 102:   F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
Figure 103:   F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
Figure 104:   F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
Figure 105:   F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
Figure 106:   F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 107:   Guardant Health: Overall Product Portfolio
Figure 108:   Guardant Health: Overall Financials, 2018-2020
Figure 109:   Guardant Health: Revenue (by Segment), 2018-2020
Figure 110:   Guardant Health: R&D Expenditure, 2018-2020
Figure 111:   Guardant Health: SWOT Analysis
Figure 112:   Illumina, Inc.: Product Portfolio
Figure 113:   Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 114:   Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 115:   Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 116:   Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 117:   Illumina, Inc.: SWOT Analysis
Figure 118:   QIAGEN N.V.: Overall Product Portfolio
Figure 119:   QIAGEN N.V.: Overall Financials, 2019-2021
Figure 120:   QIAGEN N.V.: Revenue (by Segment), 2019-2021
Figure 121:   QIAGEN N.V.: Revenue (by Region), 2019-2021
Figure 122:   QIAGEN N.V.: R&D Expenditure, 2019-2021
Figure 123:   QIAGEN N.V.: SWOT Analysis
Figure 124:   Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 125:   Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 126:   Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
Figure 127:   Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 128:   Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 129:   Thermo Fisher Scientific Inc.: SWOT Analysis

Market Report Coverage

Middle East Molecular Diagnostics Market
Base Year	2020	Market Size in 2021	$531.1 Million
Forecast Period	2021-2031	Value Projection and Estimation by 2031	$1,017.7 Million
CAGR During Forecast Period	6.72%	Number of Tables	01
Number of Pages	179	Number of Figures	129

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

•   Abbott
•   Agilent Technologies, Inc.
•   bioMérieux SA
•   BD
•   Babirus Medical Equipment LLC
•   Bio-Rad Laboratories, Inc.
•   Danaher
•   F. Hoffmann-La Roche Ltd.
•   Guardant Health
•   Illumina, Inc.
•   QIAGEN N.V.
•   Thermo Fisher Scientific Inc.

Companies that are not a part of the above-mentioned pool have been well represented across different sections of the report (wherever applicable).

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Major manufacturers of the Middle East molecular diagnostic market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.

Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly molecular diagnostics. PCR has gradually evolved from gel analysis to real-time PCR to, more recently, digital PCR. In digital PCR, amplification of individual targets is done in picolitre to nanoliter volumes, and instead of standard curves or internal controls, statistics are employed to calculate target concentrations. Genome-wide studies have gone beyond unknown expeditions, and disease association studies that use the expression, single nucleotide polymorphism, and copy number microarrays have identified useful markers that have been reduced to practical molecular tests. Big data needs have resulted in new bioinformatics tools that continue to evolve rapidly.

Competitive Strategy: Key players in the Middle East molecular diagnostics market analyzed and profiled in the study have been involved as the Middle East molecular diagnostics-based product manufacturers that provide software and molecular diagnostic services. Moreover, a detailed competitive benchmarking of the players operating in the Middle East molecular diagnostics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Industry and Technology Overview

Middle East Molecular Diagnostics Market Industry Overview

The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031. The growth in the Middle East molecular diagnostics market is expected to be driven by factors such as the increasing prevalence of infectious diseases and various types of cancer in the Middle East, rising awareness of personalized medicine and its acceptance, coupled with the significant number of funding for executing R&D in Middle East region.

Market Lifecycle Stage

Diagnostics is a well-developed market with an integral part of medical decision-making -aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. Molecular diagnostics has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the Middle East molecular diagnostics market offer products encompassing the kits and reagents, instruments, and software categories.

Increasing investments in the R&D for molecular diagnostics is one of the major opportunities in the Middle East molecular diagnostics market. Several diagnostics and pharmaceutical companies are working collaboratively to develop next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), microarray, nucleic acid amplification-, or mass spectrometry-based molecular diagnostics for the applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.

Impact

Several techniques are employed in modern molecular diagnostics to detect and quantify specific DNA or RNA sequences, as well as proteins. Some of these additional technologies are described briefly below:
•   Immunohistochemistry (IHC): IHC is the utilization of monoclonal and polyclonal antibodies for the detection of specific antigens in tissue sections.
•   In Situ Hybridization (ISH or FISH): This is a technique that unwinds DNA or RNA in the sample and employs a labeled DNA or RNA strand (probe), which hybridizes with the complementary sequence on an unwound strand (target).
•   Polymerase Chain Reaction (PCR): Polymerase chain reaction (PCR) allows researchers to amplify a small amount of DNA to quantities that can be used for analysis. PCR has ushered in a golden era in molecular diagnostics.
•   Sequencing (CE, NGS): The sequencing allows the mapping of the entire sequence of the nucleotides that comprise a strand of DNA. As of 2020, sequencing can be achieved through capillary electrophoresis (CE) or through multiple next-generation sequencing (NGS) methods.

Impact of COVID-19

The current Middle East molecular diagnostics market comprises software, instruments, and consumables. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, that have led to reduced usage of instruments, consumables, and software related to research. Overall, the impact of COVID-19 on the Middle East molecular diagnostics market size has been low-moderate. Some of the market players have reported a slight decline in sales. However, financials are already on their way to recovery. The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain. The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most of the key markets across the Middle East. However, the pandemic has played a key role in enhancing the growth prospects of molecular diagnostics and is expected to indirectly aid in improving the market growth outlook.

Market Segmentation

Segmentation 1: by Product
•   Systems
•   Kits and Consumables
•   Software and Other Products

The Middle East molecular diagnostics market in the products segment is expected to be dominated by the kits and consumables segment. This is due to an increasing number of molecular diagnostics kit providers offering kits and services to their end users.

Segmentation 2: by Testing Location
• Laboratory Testing
• Point-of-Care Testing

The Middle East molecular diagnostics market is dominated by the laboratory testing segment owing to an increasing number of molecular diagnostic laboratories in the Middle East region involved in undertaking various routine testing for different chronic and acute diseases.

Segmentation 3: by Technology
•   Polymerase Chain Reaction (PCR)
•   Next-Generation Sequencing (NGS)
•   Isothermal Nucleic Acid Amplification Technology (INAAT)
•   Microarray
•   In-Situ Hybridization (ISH)
•   Immunohistochemistry (IHC)
•   Other Technologies

The polymerase chain reaction segment dominates the Middle East molecular diagnostics market due to the increasing number of PCR testing being carried out in the Middle East laboratories for diagnosis.

Segmentation 4: by Application
•   Core Molecular Diagnostics
•   Reproductive Genetics
•   Companion Diagnostics
•   Liquid Biopsy
•   Others

Segmentation 5: by End User
•   Hospitals
•   Diagnostic Centres
•   Outpatient Clinics/General Practitioners
•   Research Laboratories
•   Others

Segmentation 6: by Country
o Kingdom of Saudi Arabia (K.S.A.)
o Israel
o United Arab Emirates (U.A.E.)
o Egypt
o Iran
o Qatar
o Other Countries

K.S.A. generated the highest revenue of $132.5 million in 2020. The Kingdom of Saudi Arabia (K.S.A.) has a huge population base suffering from various diseases and rising healthcare costs in the region. Medical research in the Kingdom of Saudi Arabia (K.S.A.) has gained momentum since 2013 and is heavily being invested in by the local government. The government is extensively supporting research organizations with projects aimed at improving the understanding and treatment of diseases affecting the Saudi population.

Recent Developments in Middle East Molecular Diagnostics Market

• In January 2022, Abbott showcased its life-changing diagnostic tools and medical devices product portfolio for point-of-care testing (POCT) that helped COVID-19, diabetes, and cardiovascular disease patients at MEDLAB Middle East.
•   In June 2021, biomeruix launched EPISEQ SARS-COV-2 to identify SARS-CoV-2 variants using samples from COVID-19 positive patients.
•   In 2021, the BD. company declared the approval of the BD Veritor At-Home COVID-19 Test for the detection of SARS-CoV-2 with definitive digital results at home.
•   In 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a Middle East leader in multiplex molecular diagnostics, for the commercialization and clinical development of molecular diagnostic products.

Demand – Drivers and Limitations

Following are the demand drivers for the Middle East Molecular Diagnostics Market:

•   Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East
•   Increase in Awareness and Acceptance of Personalized Medicines in the Middle East
•   Significant External Funding for Executing Research and Development Exercises

The market is expected to face some limitations too due to the following challenges:

• Uncertain Reimbursement Scenario
• Lack of High-Complexity Testing Centers in the Middle East

Analyst Thoughts

According to Nitish Kumar, Principal Analyst, BIS Research, “Middle East molecular diagnostics market has evolved to be an integrative aspect of healthcare routines by providing most laboratory tests equipped with infectious disease, oncology, and genetics. The massively parallel methods that have now transcended molecular diagnostics further allow the sequencing of entire genomes at very low costs. Molecular diagnostics also offers prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy.